Lineage Therap (LCTX) AI Stock Analysis
Lineage Therap
(TASE:LCTX)
No summary available
Lineage Therap (LCTX) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 255.44M
- Dividend Yield
- ―
- Average Volume (3M)
- 5,792
- Price to Earnings (P/E)
- -5.1
- Beta (1Y)
- 0.88
- Revenue Growth
- 6.09%
- EPS Growth
- 28.66%
- Country
- Israel
- Employees
- 75
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Lineage Therap Business Overview & Revenue Model
Company Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment e...
Lineage Therap Earnings Call Summary
The call presented meaningful technical and strategic progress: demonstrated scalable GMP manufacturing (AlloSCOPE), rapid internal pipeline expansion (COR1, ILT1, ReSonance), and partnership validation (Roche/Genentech, Demant). Financial reporting showed an apparent improvement to net income, extension of cash runway into Q3 2028, and an incremental $4.6M ATM raise. However, material weaknesses and near-term risks remain: Q2 revenue dropped substantially (~60.7% YoY), reported profitability was driven by noncash accounting items, cash runway still depends on contingent exercises/milestones, OpRegen advancement timing is dependent on partner-driven surgical optimization, and ILT1 faces major manufacturing scale challenges. Overall, positives around technology, partnerships and program breadth are tempered by funding, revenue dynamics and technical/partner-dependent execution risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Key guidance and metrics from the call: cash, cash equivalents and marketable securities were $50.8M as of June 30, 2026, expected to fund operations into Q3 2028; Lineage raised ≈$4.6M via an ATM on June 26 at a $1.28 weighted‑average price, is eligible for ≈$32M from warrant exercises (strike $0.91, 3‑year maturity; accelerates to 90 days on certain Roche/Genentech disclosures) and remains eligible for up to $615M in Roche/Genentech development/commercial milestones (management also cited the original collaboration included a $50M upfront + $620M in potential milestones), Q2 revenue was $1.1M (down $1.7M YoY from $2.8M), operating expenses were $10M (vs $22.5M YoY), R&D $4.8M, G&A $5.2M, loss from operations $8.9M (improved from $19.8M), other income of $10.5M from warrant remeasurement drove a net income of $1.5M (~$0.01 basic) versus a $30.5M loss a year earlier; operational milestones include OpRegen’s GAlette expansion from 6 to 17 sites and EMA IRIS registration, COR1 advancing to preclinical with in‑vivo data targeted by year‑end, AlloSCOPE 5D demonstrating a 0.5‑L suspension process and larger multi‑tier runs with a claimed ability to produce “millions” of vials, ReSonance’s Demant‑funded preclinical program (up to $12M) completing 3 engineering runs and a first GMP run now in release testing, and the DOSED study having dosed two chronic patients (one at 1 year, one at ~90 days) with no unexpected device/product‑related AEs and 1‑month DSMB pauses between the first four patients.
Lineage Therap Risk Analysis
Lineage Therap disclosed 79 risk factors in its most recent earnings report. Lineage Therap reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksLineage Therap Peers Comparison
Overall Rating
AMRN56Neutral
AURA54Neutral
FDMT54Neutral
TVRD44Neutral
DBVT42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AMRN | 56Neutral | $255.30M | -11.59 | -4.26% | ― | -22.43% | 78.01% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| AURA | 54Neutral | $636.75M | -3.39 | -73.18% | ― | ― | 9.05% |
| FDMT | 54Neutral | $657.41M | -4.18 | -41.33% | ― | 278712.12% | 26.59% |
| TVRD | 44Neutral | $10.58M | -0.29 | -145.40% | ― | -100.00% | 82.57% |
| DBVT | 42Neutral | $597.64M | -3.04 | -121.83% | ― | ― | 42.37% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:LCTX | Lineage Cell Therapeutics, Inc. | 316.80 | -266.30 | -45.67% | |
| AMRN | Amarin Corporation Plc | 12.13 | -3.18 | -20.77% | |
| TVRD | Tvardi Therapeutics Inc. | 0.81 | -3.41 | -80.92% | |
| DBVT | DBV Technologies S.A. - American Depositary Shares | 9.05 | -5.05 | -35.82% | |
| FDMT | 4D Molecular Therapeutics, Inc. | 11.37 | 0.86 | 8.18% | |
| AURA | Aura Biosciences Inc | 6.03 | 0.59 | 10.85% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.